MedTrace Logo

Long Term Vitamin D Therapy in HCV Treated Patients

NCT01997203 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-11-28

No results posted yet for this study

Summary

Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects. The purpose of this study is to determine the effect of vitamin D on liver affection in such patients.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Vitamin D

vitamin D was given to 50 patients (HCV under treatment)

Sponsors & Collaborators

  • Dr. Nadia AbdelAaty AbdelKader

    lead OTHER

Principal Investigators

  • Dina Sabry · Medical biochemistry, Cairo university

  • Mohamed M Tawfic · Tropical Medicine department, bny swif university

  • Yehia M Korriem · Tropical Medicine department, bny swif university

  • Nadia A Abdelkader · Tropical Medicine department, Ain Shams university

  • Amany Y Elkazaz · Medical Biochemistry, faculty of Medicine Suez Canal University

  • Mohamed Ghussin · Biochemistry department, faculty of Pharmacology Ghazza University.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01997203 on ClinicalTrials.gov